Answers are grounded in this paper and cite their sources.
This review summarizes advancements in adjuvants that enhance immune responses in vaccines, suggesting improved efficacy.
AbstractAdjuvants are substances distinct from antigens that enhance T and B cell activation mainly by promoting the accumulation and activation of antigen presenting cells (APCs) at the site of antigen exposure. Adjuvants (Latin: “adjuvare,” meaning “to help”) are designed to improve poorly immunogenic vaccines. Adjuvants were originally described by Ramon as ‘substances used in combination with a specific antigen that produced a more robust immune response than the antigen alone,’ thus encompassing a wide range of materials. One of the most important strategies for the development of effective new vaccines is the selection and usage of a suitable adjuvant. Immunologic adjuvants play a very important role in enhancing vaccine potency by improving the humoral and cell-mediated immune responses to vaccine antigens. In this review, we summarize the recent advances that are taking place in the development of potent adjuvants in human and veterinary vaccines.
No takes yet. Share an insight, caveat, or question.
Chandranaik et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: